
1.00
0.75
0.50
0.25
0.00
Survival Probability
0
10
20
30
Survival time, months


1.00
0.75
0.50
0.25
0.00
Survival Probability
0
10
20
30
Survival time, months
Male
Female


1.00
0.75
0.50
0.25
0.00
Survival Probability
0
10
20
30
Survival time, months
matic
atic and ambulatory
Male, In bed <50% of the day
Male, In bed > 50% of the day
Female, Asymptomatic
Female, Symptomatic and ambulatory
Fema


1.00
0.75
0.50
0.25
0.00
<function(x) x>
0
10
20
30
Survival time, months


1.00
0.75
0.50
0.25
0.00
<function(x) x>
0
10
20
30
Survival time, months
Male
Female


1.00
0.75
0.50
0.25
0.00
<function(x) x>
0
10
20
30
Survival time, months
matic
Male, In bed <50% of the day
Female, Asymptomatic
Fema
atic and ambulatory
Male, In bed > 50% of the day
Female, Symptomatic and ambulatory


1.00
0.75
0.50
0.25
0.00
Survival Probability
0
10
20
30
Survival time, months
Male
Female


1.00
0.75
0.50
0.25
Survival Probability
0
10
20
30
Survival time, months
At Risk 228 87 24 3
Events 0 103 148 165


1.00
0.75
0.50
0.25
Survival Probability
0
10
20
30
Survival time, months
At Risk 228 87 24 3
Events 0 103 148 165



Male				
At Risk	138	44	13	2
Events	0	76	103	112
Female				
At Risk	90	43	11	1
Events	0	27	45	53



Male, Asymptomatic
Male, In bed <50% of the day
Female, Asymptomatic
Male, Symptomatic and ambulatory
Male, In bed > 50% of the day
Female, Symptomatic and ambul

At Risk

Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female, In bed <50% of the day	21	7	1	0

Events

Male, Asymptomatic	0	13	24	28
Male, Symptomatic and ambulatory	0	39	51	54
Male, In bed <50% of the day	0	22	26	28
Male, In bed > 50% of the day	0	1	1	1
Female, Asymptomatic	0	4	8	9
Female, Symptomatic and ambulatory	0	12	22	28
Female, In bed <50% of the day	0	11	15	16


1.00
0.75
0.50
0.25
Survival Probability
0
10
20
30
Survival time, months
At Risk 228 87 24 3
CUM EVENTS 0 103 148 165



Male				
At Risk	138	44	13	2
CUM EVENTS	0	76	103	112
Female				
At Risk	90	43	11	1
CUM EVENTS	0	27	45	53



Male, Asymptomatic
Male, In bed <50% of the day
Female, Asymptomatic
Male, Symptomatic and ambulatory
Male, In bed > 50% of the day
Female, Symptomatic and ambul

At Risk

Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female, In bed <50% of the day	21	7	1	0

CUM EVENTS

Male, Asymptomatic	0	13	24	28
Male, Symptomatic and ambulatory	0	39	51	54
Male, In bed <50% of the day	0	22	26	28
Male, In bed > 50% of the day	0	1	1	1
Female, Asymptomatic	0	4	8	9
Female, Symptomatic and ambulatory	0	12	22	28
Female, In bed <50% of the day	0	11	15	16


1.00
0.75
0.50
0.25
Survival Probability
0
10
20
30
Survival time, months
N RISK 228 87 24 3
CUM EVENTS 0 103 148 165



Male				
N RISK	138	44	13	2
CUM EVENTS	0	76	103	112
Female				
N RISK	90	43	11	1
CUM EVENTS	0	27	45	53



Male, Asymptomatic
Male, In bed <50% of the day
Female, Asymptomatic
Male, Symptomatic and ambulatory
Male, In bed > 50% of the day
Female, Symptomatic and ambul

N RISK

Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female, In bed <50% of the day	21	7	1	0

CUM EVENTS

Male, Asymptomatic	0	13	24	28
Male, Symptomatic and ambulatory	0	39	51	54
Male, In bed <50% of the day	0	22	26	28
Male, In bed > 50% of the day	0	1	1	1
Female, Asymptomatic	0	4	8	9
Female, Symptomatic and ambulatory	0	12	22	28
Female, In bed <50% of the day	0	11	15	16



Male				
At Risk	138	44	13	2
Events	0	76	103	112
Female				
At Risk	90	43	11	1
Events	0	27	45	53



Male, Asymptomatic				
At Risk	36	18	6	1
Events	0	13	24	28
Male, Symptomatic and ambulatory				
At Risk	71	20	5	1
Events	0	39	51	54
Male, In bed <50% of the day				
At Risk	29	6	2	0
Events	0	22	26	28
Male, In bed > 50% of the day				
At Risk	1	0	0	0
Events	0	1	1	1
Female, Asymptomatic				
At Risk	27	13	2	0
Events	0	4	8	9
Female, Symptomatic and ambulatory				
At Risk	42	23	8	1
Events	0	12	22	28
Female, In bed <50% of the day				
At Risk	21	7	1	0
Events	0	11	15	16

At Risk	228	87	24	3
Events	0	103	148	165



omatic — Male, In bed <50% of the day — Female, Asymptomatic — Fem

matic and ambulatory — Male, In bed > 50% of the day — Female, Symptomatic and ambulatory

At Risk	227	87	24	3
Events	0	102	147	218


1.00
0.75
0.50
0.25
Survival Probability
0
10
20
30
Survival time, months
At Risk
Overall 228 87 24 3



	At Risk			
Overall	228	87	24	3
	Events			
Overall	0	103	148	165


1.00
0.75
0.50
0.25
Survival Probability
0
10
20
30
Survival time, months
At Risk 187 71 17 2
Events 0 85 122 133



At Risk	228	87	24	3
Events	0	103	148	165


Cumulative Incidence
0.0
0.1
0.2
0
5
10
15
20
25
Months to Death/Censor
At Risk 200 199 189 158 116 0
Events 0 0 6 24 43 57



Drug A						
At Risk	98	97	94	83	61	0
Events	0	0	2	7	17	24
Drug B						
At Risk	102	102	95	75	55	0
Events	0	0	4	17	26	33



Drug A, I Drug A, III Drug B, II
Drug A, II Drug B, I Drug B, III

At Risk

Drug A, I	35	35	35	30	22	0
Drug A, II	32	32	30	27	23	0
Drug A, III	31	30	29	26	16	0
Drug B, I	33	33	33	28	23	0
Drug B, II	36	36	32	23	17	0
Drug B, III	33	33	30	24	15	0

Events

Drug A, I	0	0	0	4	7	9
Drug A, II	0	0	1	2	3	5
Drug A, III	0	0	1	1	7	10
Drug B, I	0	0	0	3	5	9
Drug B, II	0	0	2	8	12	12
Drug B, III	0	0	2	6	9	12


Cumulative Incidence
0.0
0.1
0.2
0
5
10
15
20
25
Months to Death/Censor
At Risk 200 199 189 158 116 0
CUM EVENTS 0 0 6 24 43 57



Drug A						
At Risk	98	97	94	83	61	0
CUM EVENTS	0	0	2	7	17	24
Drug B						
At Risk	102	102	95	75	55	0
CUM EVENTS	0	0	4	17	26	33



Drug A, I Drug A, III Drug B, II
Drug A, II Drug B, I Drug B, III

At Risk

Drug A, I	35	35	35	30	22	0
Drug A, II	32	32	30	27	23	0
Drug A, III	31	30	29	26	16	0
Drug B, I	33	33	33	28	23	0
Drug B, II	36	36	32	23	17	0
Drug B, III	33	33	30	24	15	0

CUM EVENTS

Drug A, I	0	0	0	4	7	9
Drug A, II	0	0	1	2	3	5
Drug A, III	0	0	1	1	7	10
Drug B, I	0	0	0	3	5	9
Drug B, II	0	0	2	8	12	12
Drug B, III	0	0	2	6	9	12



Drug A						
At Risk	98	97	94	83	61	0
Events	0	0	2	7	17	24
Drug B						
At Risk	102	102	95	75	55	0
Events	0	0	4	17	26	33



Drug A, I						
At Risk	35	35	35	30	22	0
Events	0	0	0	4	7	9
Drug A, II						
At Risk	32	32	30	27	23	0
Events	0	0	1	2	3	5
Drug A, III						
At Risk	31	30	29	26	16	0
Events	0	0	1	1	7	10
Drug B, I						
At Risk	33	33	33	28	23	0
Events	0	0	0	3	5	9
Drug B, II						
At Risk	36	36	32	23	17	0
Events	0	0	2	8	12	12
Drug B, III						
At Risk	33	33	30	24	15	0
Events	0	0	2	6	9	12



At Risk	200	199	189	158	116	0
Events	0	0	6	24	43	57



At Risk	200	199	189	158	116	0
Events	0	0	6	24	43	57



At Risk	200	199	189	158	116	0
Events	0	1	11	42	84	11



Drug A						
At Risk	98	97	94	83	61	0
Events	0	1	4	15	37	52
Drug B						
At Risk	102	102	95	75	55	0
Events	0	0	7	27	47	60



Drug A, I Drug A, III Drug B, II death from cancer death other causes

Drug A, II Drug B, I Drug B, III

At Risk

Drug A, I	35	35	35	30	22	0
Drug A, II	32	32	30	27	23	0
Drug A, III	31	30	29	26	16	0
Drug B, I	33	33	33	28	23	0
Drug B, II	36	36	32	23	17	0
Drug B, III	33	33	30	24	15	0

Events

Drug A, I	0	0	0	5	13	16
Drug A, II	0	0	2	5	9	16
Drug A, III	0	1	2	5	15	20
Drug B, I	0	0	0	5	10	17
Drug B, II	0	0	4	13	19	20
Drug B, III	0	0	3	9	18	23


Negative
Positive
1.00
0.75
0.50
0.25
0.00
Survival Probability
0
2
4
Progression−free survival (years)
Negative
Positive



At Risk (Cum. Events)	228 (0)	87 (103)	24 (148)	3 (165)
Survival (95% CI)	% (100, 100)	52% (45, 59)	21% (16, 29)	5% (2, 12)



	Male			
At Risk (Cum. Events)	138 (0)	44 (76)	13 (103)	2 (112)
Survival (95% CI)	% (100, 100)	42% (34, 52)	15% (9, 23)	4% (1, 12)
	Female			
At Risk (Cum. Events)	90 (0)	43 (27)	11 (45)	1 (53)
Survival (95% CI)	% (100, 100)	67% (58, 78)	34% (24, 49)	8% (3, 27)



Male, Asymptomatic
Male, In bed <50% of the day
Female, Asymptomatic
Male, Symptomatic and ambulatory
Male, In bed > 50% of the day
Female, Symptomatic and ambul

At Risk (Cum. Events)

Male, Asymptomatic	36 (0)	18 (13)	6 (24)	1 (28)
Male, Symptomatic and ambulatory	71 (0)	20 (39)	5 (51)	1 (54)
Male, In bed <50% of the day	29 (0)	6 (22)	2 (26)	0 (28)
Male, In bed > 50% of the day	1 (0)	0 (1)	0 (1)	0 (1)
Female, Asymptomatic	27 (0)	13 (4)	2 (8)	0 (9)
Female, Symptomatic and ambulatory	42 (0)	23 (12)	8 (22)	1 (28)
Female, In bed <50% of the day	21 (0)	7 (11)	1 (15)	0 (16)

Survival (95% CI)

Male, Asymptomatic	(100, 100)	62% (47, 81)	23% (12, 45)	6% (1, 32)
Male, Symptomatic and ambulatory	(100, 100)	41% (30, 55)	13% (6, 28)	5% (1, 19)
Male, In bed <50% of the day	(100, 100)	24% (13, 46)	8% (2, 30)	NA% (NA, NA)
Male, In bed > 50% of the day	(100, 100)	NA% (NA, NA)	NA% (NA, NA)	NA% (NA, NA)
Female, Asymptomatic	(100, 100)	85% (73, 100)	52% (30, 88)	NA% (NA, NA)
Female, Symptomatic and ambulatory	(100, 100)	69% (56, 86)	34% (21, 57)	6% (1, 36)
Female, In bed <50% of the day	(100, 100)	41% (24, 71)	18% (6, 49)	NA% (NA, NA)


1.00
0.75
0.50
0.25
Survival Probability
0
10
20
30
Survival time, months
No. at Risk (Events) 228 (0) 87 (103) 24 (148) 3 (165)



No. at Risk (Events)

Male	138 (0)	44 (76)	13 (103)	2 (112)
Female	90 (0)	43 (27)	11 (45)	1 (53)



Male, Asymptomatic
Male, In bed <50% of the day
Female, Asymptomatic
Male, Symptomatic and ambulatory
Male, In bed > 50% of the day
Female, Symptomatic and ambul

No. at Risk (Events)

Male, Asymptomatic	36 (0)	18 (13)	6 (24)	1 (28)
Male, Symptomatic and ambulatory	71 (0)	20 (39)	5 (51)	1 (54)
Male, In bed <50% of the day	29 (0)	6 (22)	2 (26)	0 (28)
Male, In bed > 50% of the day	1 (0)	0 (1)	0 (1)	0 (1)
Female, Asymptomatic	27 (0)	13 (4)	2 (8)	0 (9)
Female, Symptomatic and ambulatory	42 (0)	23 (12)	8 (22)	1 (28)
Female, In bed <50% of the day	21 (0)	7 (11)	1 (15)	0 (16)


Cumulative Incidence
0.3
0.2
0.1
0.0
0
5
10
15
20
25
Months to Death/Censor
death from cancer
death other causes
Drug A
Drug B


Cumulative Incidence
0.0
0.1
0.2
0
5
10
15
20
25
Months to Death/Censor
death from cancer
death other causes


0.3
0.2
0.1
0.0
Cumulative Incidence
0
5
10
15
20
25
Months to Death/Censor
Drug A
Drug B


Cumulative Incidence
0.0
0.1
0.2
0.3
0
5
10
15
20
25
Months to Death/Censor
death from cancer
death other causes


1.00
0.75
0.50
0.25
0.00
estimate
0
10
20
30
time


1.00
0.75
0.50
0.25
0.00
estimate
0
10
20
30
time


1.00
0.75
0.50
0.25
Survival Probability
0
10
20
30
Survival time, months
At Risk 228 87 24 3
Events 0 103 148 165



Male				
At Risk	138	44	13	2
Events	0	76	103	112
Female				
At Risk	90	43	11	1
Events	0	27	45	53



Male, Asymptomatic
Male, In bed <50% of the day
Female, Asymptomatic
Male, Symptomatic and ambulatory
Male, In bed > 50% of the day
Female, Symptomatic and ambul

At Risk

Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female, In bed <50% of the day	21	7	1	0

Events

Male, Asymptomatic	0	13	24	28
Male, Symptomatic and ambulatory	0	39	51	54
Male, In bed <50% of the day	0	22	26	28
Male, In bed > 50% of the day	0	1	1	1
Female, Asymptomatic	0	4	8	9
Female, Symptomatic and ambulatory	0	12	22	28
Female, In bed <50% of the day	0	11	15	16


1.00
0.75
0.50
0.25
Survival Probability
0
10
20
30
Survival time, months
At Risk 228 87 24 3
Events 0 103 148 165



Male

At Risk	138	44	13	2
Events	0	76	103	112

Female

At Risk	90	43	11	1
Events	0	27	45	53



Male, Asymptomatic
Male, In bed <50% of the day
Female, Asymptomatic
Male, Symptomatic and ambulatory
Male, In bed > 50% of the day
Female, Symptomatic and ambul

At Risk

Male, Asymptomatic	36	18	6	1
Male, Symptomatic and ambulatory	71	20	5	1
Male, In bed <50% of the day	29	6	2	0
Male, In bed > 50% of the day	1	0	0	0
Female, Asymptomatic	27	13	2	0
Female, Symptomatic and ambulatory	42	23	8	1
Female, In bed <50% of the day	21	7	1	0

Events

Male, Asymptomatic	0	13	24	28
Male, Symptomatic and ambulatory	0	39	51	54
Male, In bed <50% of the day	0	22	26	28
Male, In bed > 50% of the day	0	1	1	1
Female, Asymptomatic	0	4	8	9
Female, Symptomatic and ambulatory	0	12	22	28
Female, In bed <50% of the day	0	11	15	16